C3P-No! USPTO Says No AI Inventors
Client Alert | 1 min read | 05.04.20
Last Monday, the PTO affirmed its earlier (and unsurprising) position that a patent application filed in July was incomplete because it named an artificial intelligence as the inventor. The application is believed to be among the first to name an AI as an inventor.
In reaffirming its position of AI non-inventorship, the PTO noted that the Title 35 consistently suggests personhood and refers to inventors as natural persons. As one example, said the PTO, the statutes involving the inventor oath or declaration refer to the executor as a “person.” Interpreting “inventor” to broadly encompass non-persons, argued the PTO, would contradict the plain reading of the statutes.
The USPTO also relied on Federal Circuit decisions that exclude states and corporations from holding inventorship. These decisions, the PTO noted, explain that the entire concept of “conception” – the touchstone of inventorship – requires a human mind to do the conceiving.
The attempt to name an AI as the inventor illustrates how advances in AI technology continue to challenge our traditional thinking about personhood – and how the law will have to cope with the evolving concept. Read the full decision here.
Contacts
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief



